In January 2023, it was announced that Celltrion will supply Rani’s ustekinumab biosimilar drug substance, CT-P43, for the oral RT-111 RaniPill programme. Now, in June 2023, a second deal is made that Celltrion will exclusively supply Rani with the adalimumab biosimilar drug substance (CT-P17) required for its RT-105 RaniPill.

In 2021 and 2022, Rani announced the launch and development of new oral, needle-free methods to deliver large biological drug molecules, such as ustekinumab [1] and adalimumab [2]. These are known as RaniPills RT-111 and RT-105, respectively. The RaniPill capsule is designed to administer biologicals with bioavailability comparable to subcutaneous injection.

The recent partnership will see the development and supply of the biosimilars for these pills. Under the terms of the agreement, Celltrion will exclusively supply to Rani the ustekinumab (CT-P43) and adalimumab (CT-P17) biosimilar drug substances required for the RaniPills. Rani is granted an exclusive license to use CT-P43 and CT-P17 in the development and commercialization of RT-111 and RT-105, and Celltrion is granted a right of first negotiation to acquire worldwide rights to RT-111 and RT-105 following a phase I clinical trial.

Related articles
New adalimumab biosimilars prepare to launch in Canada, US and Europe

Amgen announces positive phase III results for ustekinumab biosimilar

References
1. GaBI Online - Generics and Biosimilars Initiative. Ustekinumab biosimilars: new international biopharma agreements [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jul 14]. Available from: www.gabionline.net/pharma-news/ustekinumab-biosimilars-new-international-biopharma-agreements
2. GaBI Online - Generics and Biosimilars Initiative. Needle-free delivery of biological drugs from Rani and Progenity (gabionline.net) [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jul 14]. Available from: www.gabionline.net/biosimilars/general/needle-free-delivery-of-biological-drugs-from-rani-and-progenity

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.